Bernard R Chaitman

Summary

Affiliation: Saint Louis University
Country: USA

Publications

  1. ncbi Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina
    Bernard R Chaitman
    Core ECG Laboratory, Saint Louis University School of Medicine, St Louis, Missouri 63117, USA
    J Am Coll Cardiol 43:1375-82. 2004
  2. ncbi Antianginal efficacy of omapatrilat in patients with chronic angina pectoris
    Bernard R Chaitman
    Saint Louis University School of Medicine, St Louis, Missouri 63117, USA
    Am J Cardiol 95:1283-9. 2005
  3. ncbi Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease
    Bernard R Chaitman
    Saint Louis University School of Medicine, Division of Cardiology, USA
    Clin Cardiol 30:I25-30. 2007
  4. ncbi Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials
    Bernard R Chaitman
    Saint Louis University School of Medicine, St Louis, MO 63117, USA
    J Cardiovasc Pharmacol Ther 9:S47-64. 2004
  5. ncbi Should ECG be required in young athletes?
    Bernard R Chaitman
    Department of Medicine, Division of Cardiology, Saint Louis University School of Medicine, St Louis, MO 63117, USA
    Lancet 371:1489-90. 2008
  6. ncbi An electrocardiogram should not be included in routine preparticipation screening of young athletes
    Bernard R Chaitman
    St. Louis University School of Medicine, Division of Cardiology, 1034 S Brentwood Blvd, Suite 1550, St. Louis, MO 63117, USA
    Circulation 116:2610-4; discussion 2615. 2007
  7. ncbi Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial
    Bernard R Chaitman
    Department of Medicine, Division of Cardiology, St Louis University School of Medicine, St Louis, MO, USA
    JAMA 291:309-16. 2004
  8. ncbi Pharmacological approaches to the symptomatic treatment of chronic stable angina: a historical perspective and future directions
    Bernard R Chaitman
    St Louis University Core ECG Laboratory, St Louis, MI 63117, USA
    Can J Cardiol 21:1031-4. 2005
  9. ncbi A review of the GUARDIAN trial results: clinical implications and the significance of elevated perioperative CK-MB on 6-month survival
    Bernard R Chaitman
    St Louis University School of Medicine, St Louis, Missouri 63117, USA
    J Card Surg 18:13-20. 2003
  10. ncbi Do major cardiovascular outcomes in patients with stable ischemic heart disease in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial differ by healthcare system?
    Bernard R Chaitman
    Department of Internal Medicine, Saint Louis University School of Medicine, 1034 S Brentwood Blvd, St Louis, MO 63117, USA
    Circ Cardiovasc Qual Outcomes 3:476-83. 2010

Detail Information

Publications47

  1. ncbi Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina
    Bernard R Chaitman
    Core ECG Laboratory, Saint Louis University School of Medicine, St Louis, Missouri 63117, USA
    J Am Coll Cardiol 43:1375-82. 2004
    ..The primary objective of the Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) trial was to determine the dose-response relationship of ranolazine, a potentially new anti-anginal compound, on symptom-limited exercise duration...
  2. ncbi Antianginal efficacy of omapatrilat in patients with chronic angina pectoris
    Bernard R Chaitman
    Saint Louis University School of Medicine, St Louis, Missouri 63117, USA
    Am J Cardiol 95:1283-9. 2005
    ..The data confirm the proof of principle that broader vasopeptidase inhibition beyond angiotensin-converting enzyme inhibition is required to alleviate symptoms of chronic angina...
  3. ncbi Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease
    Bernard R Chaitman
    Saint Louis University School of Medicine, Division of Cardiology, USA
    Clin Cardiol 30:I25-30. 2007
    ..In this review, several other novel investigational approaches are presented and patient selection considerations for the most recent approved drugs for chronic angina are discussed...
  4. ncbi Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials
    Bernard R Chaitman
    Saint Louis University School of Medicine, St Louis, MO 63117, USA
    J Cardiovasc Pharmacol Ther 9:S47-64. 2004
    ..In conclusion, clinical trial evidence with ranolazine to date is consistent with its proposed mechanism of action and demonstrates an effective antianginal profile that may benefit patients with severe chronic angina...
  5. ncbi Should ECG be required in young athletes?
    Bernard R Chaitman
    Department of Medicine, Division of Cardiology, Saint Louis University School of Medicine, St Louis, MO 63117, USA
    Lancet 371:1489-90. 2008
  6. ncbi An electrocardiogram should not be included in routine preparticipation screening of young athletes
    Bernard R Chaitman
    St. Louis University School of Medicine, Division of Cardiology, 1034 S Brentwood Blvd, Suite 1550, St. Louis, MO 63117, USA
    Circulation 116:2610-4; discussion 2615. 2007
  7. ncbi Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial
    Bernard R Chaitman
    Department of Medicine, Division of Cardiology, St Louis University School of Medicine, St Louis, MO, USA
    JAMA 291:309-16. 2004
    ....
  8. ncbi Pharmacological approaches to the symptomatic treatment of chronic stable angina: a historical perspective and future directions
    Bernard R Chaitman
    St Louis University Core ECG Laboratory, St Louis, MI 63117, USA
    Can J Cardiol 21:1031-4. 2005
    ..Indeed, the mechanism whereby nitroglycerin exerts its action took 130 years to fully understand. The experimental drugs discussed in the present review are currently not approved for use in North America...
  9. ncbi A review of the GUARDIAN trial results: clinical implications and the significance of elevated perioperative CK-MB on 6-month survival
    Bernard R Chaitman
    St Louis University School of Medicine, St Louis, Missouri 63117, USA
    J Card Surg 18:13-20. 2003
    ....
  10. ncbi Do major cardiovascular outcomes in patients with stable ischemic heart disease in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial differ by healthcare system?
    Bernard R Chaitman
    Department of Internal Medicine, Saint Louis University School of Medicine, 1034 S Brentwood Blvd, St Louis, MO 63117, USA
    Circ Cardiovasc Qual Outcomes 3:476-83. 2010
    ..The primary aim of this study was to determine whether there is a treatment difference in cardiovascular outcomes by HCS...
  11. ncbi Stable angina pectoris: antianginal therapies and future directions
    Bernard R Chaitman
    Department of Medicine, Division of Cardiology, Saint Louis University School of Medicine, 1034 South Brentwood Boulevard, Suite 1550, St Louis, MO 63117, USA
    Nat Rev Cardiol 9:40-52. 2012
    ..Finally, trials to investigate stimulation of angiogenesis using growth-factor, gene, and cell therapy are used to illustrate the challenges of chemically inducing the growth of adequate, durable blood vessels...
  12. ncbi Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions
    Bernard R Chaitman
    Division of Cardiology, Department of Medicine, St Louis University School of Medicine, St Louis, MO 63117, USA
    Circulation 113:2462-72. 2006
  13. ncbi Choice of initial medical therapy vs. prompt coronary revascularization in patients with type 2 diabetes and stable ischemic coronary disease with special emphasis on the BARI 2D trial results
    Bernard R Chaitman
    Department of Medicine, Saint Louis University School of Medicine, St Louis, Missouri 63117, USA
    Curr Opin Cardiol 25:597-602. 2010
    ....
  14. ncbi The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarctio
    Bernard R Chaitman
    St Louis University School of Medicine, 1034 S Brentwood Blvd, St Louis, MO 63117, USA
    Circulation 120:2529-40. 2009
    ..In this report, we examine the predefined secondary end points of cardiac death and myocardial infarction (MI)...
  15. ncbi Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial
    David J Maron
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Am Coll Cardiol 58:131-7. 2011
    ..Our purpose was to clarify the clinical utility of identifying metabolic syndrome (MetS) in patients with coronary artery disease (CAD)...
  16. ncbi Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 119:2032-9. 2009
    ..We designed a prospective evaluation of the effect of ranolazine on hyperglycemia as part of a randomized, double-blind, placebo-controlled outcomes trial...
  17. ncbi Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial
    Sean R Wilson
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 53:1510-6. 2009
    ..We aimed to evaluate the efficacy and safety of ranolazine in a larger and more diverse group of patients with angina than previously studied...
  18. ncbi Prognostic significance of elevated creatine kinase MB after coronary bypass surgery and after an acute coronary syndrome: results from the GUARDIAN trial
    Jeffrey A Gavard
    Division of Cardiology, 15th Floor, St. Louis University School of Medicine, 3635 Vista Avenue at Grand Boulevard, PO Box 15250, St. Louis, MO 63110-0250, USA
    J Thorac Cardiovasc Surg 126:807-13. 2003
    ..Newer cardioprotective agents that reduce the number of patients with marked creatine kinase-myocardial band release are currently being tested in large randomized controlled clinical trials...
  19. ncbi Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor
    Bernard R Chaitman
    St. Louis University School of Medicine, St. Louis, MO, USA
    Curr Probl Cardiol 27:527-55. 2002
  20. ncbi Electrocardiography screening for cardiotoxicity after modified Vaccinia Ankara vaccination
    Junko Sano
    The Saint Louis University School of Medicine, Department of Medicine, Division of Cardiology, St Louis, MO 63117, USA
    Am J Med 122:79-84. 2009
    ..Symptomatic myopericarditis has been described after smallpox vaccination using replication-competent vaccinia strains...
  21. ncbi The value of estimated functional capacity in estimating outcome: results from the NHBLI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study
    Leslee J Shaw
    Division of Cardiology, Department of Medicine, Cedars Sinai Research Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Am Coll Cardiol 47:S36-43. 2006
    ..Our objective was to determine the prognostic value of estimated metabolic equivalents (METs) based on self-reported functional capacity by the Duke Activity Status Index (DASI) in symptomatic women...
  22. ncbi Liberal or restrictive transfusion in high-risk patients after hip surgery
    Jeffrey L Carson
    Division of General Internal Medicine, Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA
    N Engl J Med 365:2453-62. 2011
    ..We conducted a randomized trial to determine whether a higher threshold for blood transfusion would improve recovery in patients who had undergone surgery for hip fracture...
  23. ncbi Images in clinical medicine. Electrocardiographic changes in intracranial hemorrhage mimicking myocardial infarction
    W Brian Bailey
    Saint Louis University School of Medicine, St. Louis, MO 63110-0250, USA
    N Engl J Med 349:561. 2003
  24. ncbi Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy
    David D Waters
    Division of Cardiology, San Francisco General Hospital, and the University of California, San Francisco School of Medicine, San Francisco, Calif 94110, USA
    Circulation 106:1690-5. 2002
    ..4% in the placebo group to 14.8% in the atorvastatin group over the 16 weeks of the trial (P=0.048)...
  25. ncbi Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge
    Sharon E Frey
    Department of Medicine, Saint Louis University School of Medicine and National Institute of Allergy and Infectious Diseases Vaccine Treatment and Evaluation Unit, 1100 S Grand Blvd DRC 8, St Louis, MO 63104, USA
    Vaccine 25:8562-73. 2007
    ..IMVAMUNE vaccination prior to Dryvax reduced virus replication at the Dryvax site, decreased the size of the primary cutaneous lesion, and decreased the time to healing but did not completely ameliorate the immune response...
  26. ncbi Transfusion trigger trial for functional outcomes in cardiovascular patients undergoing surgical hip fracture repair (FOCUS)
    Jeffrey L Carson
    Division of General Internal Medicine, Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
    Transfusion 46:2192-206. 2006
  27. ncbi Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy
    Leslee J Shaw
    Emory University School of Medicine, Atlanta, GA 30306, USA
    Circulation 117:1283-91. 2008
    ....
  28. ncbi Optimal medical therapy with or without PCI for stable coronary disease
    William E Boden
    Western New York Veterans Affairs Healthcare Network and Buffalo General Hospital SUNY, Buffalo, NY 14203, USA
    N Engl J Med 356:1503-16. 2007
    ....
  29. ncbi No reflow and the quest to achieve optimal perfusion during the acute phase of myocardial infarction
    Bernard R Chaitman
    J Am Coll Cardiol 44:313-5. 2004
  30. ncbi Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes
    Adam D Timmis
    Department of Cardiology, London Chest Hospital, Bonner Road, London E2 9JX, UK
    Eur Heart J 27:42-8. 2006
    ..Glycaemic control was also assessed in CARISA and its long-term open-label extension study...
  31. ncbi ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines)
    Raymond J Gibbons
    J Am Coll Cardiol 40:1531-40. 2002
  32. ncbi ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines)
    Raymond J Gibbons
    Circulation 106:1883-92. 2002
  33. ncbi Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases
    Barry J Maron
    Circulation 109:2807-16. 2004
    ....
  34. ncbi ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery--Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guide
    Kim A Eagle
    Anesth Analg 94:1052-64. 2002
  35. ncbi Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or =75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, a
    Mark A Williams
    Circulation 105:1735-43. 2002
  36. ncbi Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention
    Ileana L Pina
    Circulation 107:1210-25. 2003
  37. ncbi Clinical assessment and management of patients with implanted cardioverter-defibrillators presenting to nonelectrophysiologists
    William G Stevenson
    Circulation 110:3866-9. 2004
    ....
  38. ncbi ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guide
    Kim A Eagle
    J Am Coll Cardiol 39:542-53. 2002
  39. ncbi Abnormal heart rate responses to exercise predict increased long-term mortality regardless of coronary disease extent: the question is why?
    Bernard R Chaitman
    J Am Coll Cardiol 42:839-41. 2003
  40. ncbi Should early acceleration of heart rate during exercise be used to risk stratify patients with suspected or established coronary artery disease?
    Bernard R Chaitman
    Circulation 115:430-1. 2007
  41. ncbi Task Force 6: coronary artery disease
    Paul D Thompson
    J Am Coll Cardiol 45:1348-53. 2005
  42. ncbi Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues
    E Marc Jolicoeur
    Duke University, Durham, NC, USA
    Am Heart J 155:435-44. 2008
    ..The present part reviews the current status of understanding of advanced CAD, the limits of contemporary therapies, and the difficulties in and barriers to the development of new treatments...
  43. ncbi Clinical and research issues regarding chronic advanced coronary artery disease: part I: Contemporary and emerging therapies
    E Marc Jolicoeur
    Duke University, Durham, NC, USA
    Am Heart J 155:418-34. 2008
    ..Trial design, end points, and regulatory issues will be discussed in the second part of the article...
  44. ncbi Task force 2: training in electrocardiography, ambulatory electrocardiography, and exercise testing
    Robert J Myerburg
    J Am Coll Cardiol 51:348-54. 2008
  45. ncbi Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424
    William E Boden
    VA Connecticut Healthcare System, West Haven, CT, USA
    Am Heart J 151:1173-9. 2006
    ....
  46. ncbi The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
    William E Boden
    VA Connecticut Healthcare System, West Haven, Connecticut, USA
    Am J Cardiol 99:208-12. 2007
    ....
  47. ncbi ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery---executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guide
    Kim A Eagle
    Circulation 105:1257-67. 2002